MDLN vs. ZBH: Medline vs. Zimmer Biomet Stock Comparison

Company Profile

Medline (MDLN) and Zimmer Biomet (ZBH) both belong to the Health Care Equipment & Supplies industry, though MDLN is classified under Health Care Supplies while ZBH falls under Health Care Equipment.

Zimmer Biomet (ZBH) has been public since July 25, 2001, giving it decades of market history across multiple cycles, while Medline (MDLN) listed only on December 17, 2025 and lacks comparable through-cycle data.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Zimmer Biomet (ZBH) has a non-negative beta of 0.42.

Risk-Adjusted Performance

Risk-Return Positioning

Both MDLN and ZBH need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Medline (MDLN) at 4.85% and Zimmer Biomet (ZBH) at 6.03% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Both Medline (MDLN) at 1.85% and Zimmer Biomet (ZBH) at 8.95% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Zimmer Biomet (ZBH) at 17.35% operates in the top operating margin quartile, ahead of Medline (MDLN) at 5.22%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: Zimmer Biomet (ZBH) reports revenue growth of 7.20%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than Zimmer Biomet (ZBH) at -19.86%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Zimmer Biomet (ZBH) at 1.46 keeps current ratio within its industry’s typical mid-range, while Medline (MDLN) at 4.04 sits above its industry’s typical mid-range — comfortable liquidity, though possibly with more idle current assets relative to peers.

Both Medline (MDLN) at 0.65 and Zimmer Biomet (ZBH) at 0.60 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Medline (MDLN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zimmer Biomet (ZBH) reports a yield of 0.90%, ranking against industry peers normally.

Medline (MDLN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zimmer Biomet (ZBH) reports a payout of 24.24%, ranking against industry peers normally.

Dividend Metrics

Valuation

Zimmer Biomet (ZBH) at 26.66 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

On P/S ratio, both Medline (MDLN) at 1.70 and Zimmer Biomet (ZBH) at 2.33 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Zimmer Biomet (ZBH) at 1.58 sits in the lower P/B ratio quartile against book while Medline (MDLN) at 2.95 is valued near its industry’s middle — ZBH is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics